ReviewFundamental research2026
Recent advances in ultrasound-targeted nanobubbles combined with cancer immunotherapy: Mechanisms, applications, and challenges.
Review in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sonocavitation therapy for pancreatic cancer: Research progress, clinical application and future perspectives.iScience · 2026Review
- Review
- Quantification of Kidney Inflammation Using Nanobubble-mediated Contrast Enhanced Ultrasound.Nanotheranostics · 2026Article
- New strategies for tumor diagnosis and therapy with ultrasound assisted by nanomaterials.Ultrasonics sonochemistry · 2025Review
- Acoustic immune reprogramming: a novel paradigm for spatiotemporally controlled immune regulation using ultrasound-responsive nanoplatforms.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has revolutionized cancer treatment by leveraging the immune system to target tumors. However, its efficacy is often limited by the immunosuppressive tumor microenvironment and the development of resistance, leading to response rates of only 20%-30%. Ultrasound-targeted nanobubbles (UTN) combined with cancer immunotherapy present a promising solution to the limitations of current treatments. By utilizing the mechanical and biological effects of ultrasound, UTN improve drug delivery, reduce systemic toxicity, and modulate immune responses within the tumor microenvironment. Preclinical studies have shown that UTN combined with cancer immunotherapy can significantly increase the use of checkpoint inhibitors, tumor vaccines, and gene-based therapies, resulting in better tumor control. This article reviews the latest advancements, applications, and challenges of UTN combined with cancer immunotherapy, emphasizing the potential of UTN to overcome current therapeutic barriers and providing a forward-looking perspective on its translation into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.